MedTrace Logo

DOAC ADRs Retrospective Study on Genetic Variations

NCT04580589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2023-02-16

No results posted yet for this study

Summary

The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e. serious bleeding) that the participant may have experienced since taking the drug (direct oral anticoagulant) for preventing blood clots from forming in the blood vessels.

Conditions

  • Drug-Related Side Effects and Adverse Reactions
  • Treatment Failure

Sponsors & Collaborators

  • Santa Clara Valley Medical Center

    collaborator OTHER

  • Cipherome, Inc.

    lead INDUSTRY

Principal Investigators

  • Dayani Nualles-Percy, MD · Santa Clara Valley Medical Center

  • Clifford Wang, MD · Santa Clara Valley Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580589 on ClinicalTrials.gov